China NMPA Approves Rufexibart Subcutaneous Injection for HoFH

The significance here is less about the drug's mechanism than about what a priority review signals: Chinese regulators are moving faster on rare-disease therapies, and a domestic developer is now competing in a space where HoFH patients have historically had few options. The direct beneficiaries are a narrow population — adults and adolescents aged 12 and older with this severe inherited condition — so the commercial footprint will be small even if the clinical value is high. Worth watching is whether the combination-therapy labeling and the subcutaneous route change real-world adherence patterns, and whether this approval becomes a template for other domestic rare-disease filings.